Printer Friendly

SANDOZ REPORTS NEW STUDY CONFIRMS BENEFITS OF CLOZARIL THERAPY AND MONITORING

 EAST HANOVER, N.J., July 16 /PRNewswire/ -- Sandoz Pharmaceuticals Corporation reported today that the study "Clozapine-Induced Agranulocytosis - Incidence and Risk Factors in the United States," and accompanying editorial, in the July 15, 1993 edition of "The New England Journal of Medicine" clearly documents Clozaril(R) therapy can be successfully managed with weekly blood monitoring. Currently, weekly blood monitoring is carried out through Clozaril Treatment Systems, partnerships of physicians and pharmacists formed through Sandoz' Clozaril National Registry.
 Clozaril, an atypical antipsychotic medication discovered and marketed by Sandoz, is considered the first major breakthrough in schizophrenia in 40 years. Clozaril is indicated for patients with schizophrenia who have not achieved an adequate response to standard neuroleptics or who experience intolerable side effects from traditional therapies.
 The study conducted by researchers at the Hillside Hospital Division of Long Island Jewish Medical Center, the Albert Einstein College of Medicine, and Sandoz assessed the rates and development of agranulocytosis, a potentially fatal blood disorder associated with Clozaril therapy. The researchers determined that while agranulocytosis is a clinical risk, weekly blood monitoring of the more than 11,500 patients in the study resulted in an actual incidence of agranulocytosis of less than one percent in comparison to the expected one-to-two percent incidence.
 "The good news for practitioners is that therapeutic approaches to schizophrenia that involve Clozaril therapy provide patients with the benefits available in symptom control and functional improvements. What's more, the risk of therapy can be successfully managed with weekly monitoring by physicians and pharmacists, thereby helping to ensure patient safety," stated Gil Honigfeld, Ph.D., director of scientific affairs, Sandoz.
 According to Sandoz, the Clozaril package labeling requires weekly blood tests. The company further noted that it concurs with the conclusions of the study and editorial authors that additional data and analysis are required before any recommendation on changing the frequency of Clozaril patient blood monitoring can be made.
 -0- 7/16/93
 /CONTACT: William O'Donnell of Sandoz Pharmaceuticals Corporation, 201-503-7070/


CO: Sandoz Pharmaceuticals Corporation ST: New Jersey IN: MTC SU:

PS-OS -- NY022 -- 2452 07/16/93 12:11 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 16, 1993
Words:346
Previous Article:AMCLYDE BUYS PATENTED DEEPWATER MOORING EQUIPMENT
Next Article:P.C. RICHARD & SONS ANNOUNCES FILING OF AMENDMENT TO A REGISTRATION STATEMENT RELATING TO AN INITIAL PUBLIC OFFERING
Topics:


Related Articles
STUDY POINTS TO NEW HOPE FOR MIGRAINE SUFFERERS IN 50-YEAR-OLD DRUG
SANDOZ PHARMACEUTICALS SETTLES LITIGATION
SANDOZ PHARMACEUTICALS SETTLES LITIGATION
SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE THAT CPMP RECOMMENDS APPROVAL 'LEUCOMAX' IN EUROPEAN COMMUNITY
NATIONAL INSTITUTE ON AGING UNIT ANNOUNCES CLINICAL TRIAL FOR TREATMENT OF ALZHEIMER'S DISEASE
MIGRAINE NASAL SPRAY PROVIDES SAFE, EFFECTIVE RELIEF OF HEADACHE PAIN AND NAUSEA, CONCLUDES RECENT STUDY AT UNIVERSITY OF KANSAS MEDICAL CENTER
SANDOZ' NEORAL RECOMMENDED AS TREATMENT FOR THE PROPHYLAXIS OF ORGAN REJECTION BY ADVISORY COMMITTEE TO THE FDA
SANDOZ' NEORAL(R) CLEARED FOR MARKETING BY THE FDA FOR THE PREVENTION OF ORGAN REJECTION
PRELIMINARY FINDINGS WITH LESCOL IN CORONARY HEART DISEASE
Unique Clozaril National Registry Paramount to Patient Safety

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters